Alzheimer Disease and Its Management
Authors:
- Malay K SamantaMSMalay K Samanta
- B WilsonBWB Wilson
- K SanthiKSK Santhi
- K P Sampath KumarKKK P Sampath Kumar
- B SureshBSB Suresh
- 1 November 2006
- journal article
- review article
- Published by Wolters Kluwer Health in American Journal of Therapeutics
- Vol. 13 (6) , 516-526
Abstract
Alzheimer disease is a progressive degenerative disorder of the brain characterized by a slow, progressive decline in cognitive function and behavior. As the disease advances, persons with Alzheimer disease have tough time with daily usage of things like using the phone, cooking, handling money, or driving the car. The disease is more common in elder population. It is estimated that Alzheimer disease affects 15 million people worldwide and approximately 4 million Americans. The clinical features of Alzheimer disease overlaps with common signs of aging, and other types of dementia, hence the diagnosis remains difficult. The neuropathologic hallmarks of the disorder are amyloid-rich senile plaques, neurofibrillary tangles, and neuronal degeneration. Drugs approved for treating Alzheimer disease include acetylcholinesterase inhibitors and N-methyl-D-aspartate (NMDA) receptor antagonist. Caregivers not getting adequate information about Alzheimer disease may believe that nothing can be done to manage its symptoms. Understanding the extent of Alzheimer disease related knowledge can assist disease management that result in improved disease management and reduced care costs. This article attempts to focus on some of the important recent developments in understanding and management of Alzheimer disease.Keywords
This publication has 95 references indexed in Scilit:
- Memantine Treatment in Patients With Moderate to Severe Alzheimer Disease Already Receiving DonepezilJAMA, 2004
- Efficacy and Tolerability of Donepezil in Vascular DementiaStroke, 2003
- MemantineDrugs & Aging, 2003
- DonepezilDrugs & Aging, 2003
- Resource Utilisation and Cost Analysis of Memantine in Patients with Moderate to Severe Alzheimer??s DiseasePharmacoEconomics, 2003
- Clinical Pharmacokinetics and Pharmacodynamics of Cholinesterase InhibitorsClinical Pharmacokinetics, 2002
- Treatment of Alzheimer's DiseaseNew England Journal of Medicine, 1999
- Cholinesterase Inhibitors in the Treatment of Alzheimer??s DiseaseDrug Safety, 1998
- Long-term tacrine treatment in patients with Alzheimer's diseaseThe Lancet, 1996
- Stereoselectivity of pesticides: Biological and chemical problems (Chemicals in agriculture, vol. 1)Trends in Pharmacological Sciences, 1989